Skip to main content

Surrozen, Inc.

corporate_fare Company Profile

Surrozen, Inc.

SRZN·NASDAQ·Life Sciences·CIK 0001824893

We are a biotechnology company focused on discovering and developing product candidates that selectively adjust the Wnt pathway, which is crucial for tissue repair. Our primary focus is ophthalmology, where Wnt signaling is vital for retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our goal is to revolutionize the treatment of serious eye diseases by fully utilizing the Wnt pathway. Based on the foundational work of our founders and scientific advisors who identified the Wnt gene and its key regulators, we have made significant discoveries. These discoveries allow us to rapidly and flexibly create tissue-targeted treatments that modulate Wnt signaling, forming the basis of our ophthalmology portfolio and research programs. These programs aim to restore tissue structure and function in serious eye diseases with significant unmet medical needs. Our main product candidates are multi-specific, antibody-based treatments that imitate natural Wnt proteins, which activate and enhance the Wnt pathway. Wnt signaling is essential for tissue maintenance and regeneration throughout the body. Our current development efforts are concentrated on ophthalmology because the Wnt pathway's biology is clinically proven in this area, and localized delivery allows for controlled therapeutic modulation. Our strategy involves identifying diseases responsive to Wnt modulation, designing tissue-selective treatments, evaluating mechanisms that complement Wnt signaling, and advancing candidates into clinical development for specific ophthalmic conditions with high unmet need. Our approach and platform technologies have led to the discovery and advancement of multiple product candidates. We believe ophthalmology indications are particularly suitable for Wnt modulating therapeutics due to strong genetic and biological validation and the need for methods to restore tissue structure and function.

Surrozen, Inc. (NASDAQ:SRZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for SRZN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Director and 10% Owner Tim Kutzkey Buys $300K in SRZN Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.48M
Net Income
-$242.03M
Diluted EPS
-$32.37
Op. Cash Flow
-$30.24M
Free Cash Flow
-$30.37M
Operating Income
-$42.09M
Cash & Equivalents
$89.25M
Debt / Equity
0.00×
Net Margin
-69.61×
Shares Outstanding
9.78M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-119818
$31.5 +2.71% today
52-week range · as of 2026-11-09 $11.51 – $37.83
Market cap
$542.49M
Volume
148.8K (0.4× avg)
3-mo avg 343.2K
Live data · 2026-11-22 12:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SRZN - Filings & News (Page 2)

SRZN
Jan 08, 2026, 5:19 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $19.06
Real-time Price: $31.50 info
Change: +$12.44 (+65%) info
Market Cap: $542.495M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets